Agreement - May 12, 2023
Alligator and Orion announce exercise of development option
Alligator Bioscience has announced that Orion Corporation has selected bispecific lead antibodies and is exercising its option to develop these molecules under the existing research collaboration and license agreement between the two companies. Alligator will continue to generate additional data in order for Orion to select the final development candidate over the coming months. Upon […]
Acquisition - May 10, 2023
Sobi to acquire CTI BioPharma for 1.7 billion USD
Swedish Orphan Biovitrum (Sobi) has entered into an agreement and plan of merger with CTI BioPharma (CTI) under which Sobi has agreed to acquire CTI, by means of a tender offer. Sobi is to commence a cash tender offer to acquire all issued and outstanding shares of CTI for USD 9.10 per share, corresponding to […]
Biotech Business - May 10, 2023
AstraZeneca’s Koselugo approved in China
Koselugo (selumetinib) has been approved in China for the treatment of symptomatic, inoperable plexiform neurofibromas (PN) in paediatric patients with neurofibromatosis type 1 (NF1) aged three years and above. “Koselugo offers hope for children whose quality of life and overall well-being is impacted by the growth of painful, debilitating tumours throughout the body. We are […]
Agreement - May 8, 2023
Neuro3 therapeutics acquires exclusive worldwide rights from Lundbeck
The agreement focuses on activators of KCNQ2, an ion channel that has been clinically validated as a target for the treatment of epilepsy. Clinical findings suggest that activation of KCNQ2 channels may provide treatment options for other types of neurological disorders including rare forms of epilepsy. Read more: Lundbeck and Alloy Therapeutics collaborate Under the […]
Agreement - May 4, 2023
XNK Therapeutics in agreement with global pharma company
The company’s autologous natural killer (NK) cell therapy candidate XNK04 will be evaluated in combination with an ADCC competent PD-L1 inhibitor in liver cancer under a research agreement with a global pharma company. The preclinical validation study aims to test the cell therapy candidate XNK04 alone and in combination with an antibody checkpoint inhibitor against […]
Biotech Business - April 26, 2023
Xbrane and STADA supply Ximluci in England
The two companies are now supplying Ximluci (ranibizumab biosimilar) in England via a National Health Service (NHS) England Framework Agreement. The partners announced in January 2023 that the UK’s Medicines and Healthcare products Regulatory Agency (MHRA) had granted a marketing authorization for Ximluci (ranibizumab), a biosimilar referencing Lucentis. Under the co-development agreement in operation since […]
